Sumitomo Pharma (DNPUF) Stock Forecast & Price Target

$2.70
0.00 (0.00%)
(As of 04/25/2024 ET)

Sumitomo Pharma Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 1 Analyst Ratings

Analysts' Consensus Price Target

N/A

TypeCurrent Forecast
4/27/23 to 4/26/24
1 Month Ago
3/28/23 to 3/27/24
3 Months Ago
1/27/23 to 1/27/24
1 Year Ago
4/27/22 to 4/27/23
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
1 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetN/AN/AN/AN/A
Predicted UpsideN/AN/AN/AN/A
Get Sumitomo Pharma Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for DNPUF and its competitors with MarketBeat's FREE daily newsletter.

DNPUF Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DNPUF Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Sumitomo Pharma Stock vs. The Competition

TypeSumitomo PharmaMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.68
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside924.72% Upside10.18% Upside
News Sentiment RatingNegative News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/22/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 04:06 PM ET.

DNPUF Price Target - Frequently Asked Questions

What is Sumitomo Pharma's consensus rating?

According to the issued ratings of 1 analysts in the last year, the consensus rating for Sumitomo Pharma stock is Hold based on the current 1 hold rating for DNPUFthe . Learn more on DNPUF's analyst rating history.

Do Wall Street analysts like Sumitomo Pharma more than its competitors?

Analysts like Sumitomo Pharma less than other Medical companies. The consensus rating for Sumitomo Pharma is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how DNPUF compares to other companies.


Stock Ratings Reports and Tools

Related Companies:
This page (OTCMKTS:DNPUF) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners